MenoGeniX
MenoGeniX is a privately-held, clinical-stage biopharmaceutical company developing MNGX-100, a G-CSF analog for treating moderate-to-severe menopausal hot flashes as an alternative to hormone therapy and paroxetine. The company is funded by NIH and equity capital and seeks a commercialization partner.
- Company typePrivate
- Founded2010
- HeadquartersAurora, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What MenoGeniX does
MenoGeniX is a privately-held, clinical-stage biopharmaceutical company headquartered in Aurora, Colorado, adjacent to the University of Colorado Anschutz Medical Campus. Founded in 2010 by Debra Duke and co-founded with Douglas Farrar and Richard C. Duke, the company is dedicated to developing a non-hormonal, non-antidepressant treatment for moderate and severe hot flashes and related vasomotor symptoms in women experiencing naturally occurring or surgically induced menopause. MenoGeniX serves a large unmet need: over 10 million U.S. women aged 50-65 experience menopausal hot flashes, and only two FDA-approved pharmacologic options (hormone therapy and low-dose paroxetine) currently exist.
The company's lead and only disclosed product candidate, MNGX-100, contains an analog of the naturally occurring human protein granulocyte colony-stimulating factor (G-CSF). MenoGeniX's mechanistic thesis is that G-CSF acts on the hypothalamus — the body's thermostat — to counteract proinflammatory cytokines that are elevated in symptomatic menopausal women. A multicenter, double-blind, randomized, placebo-controlled Phase I trial in 30 women has been completed, and an NIA/NIH-funded Phase Ib/IIa trial evaluating multiple doses in 60 women is in progress. MNGX-100 is protected by an issued patent portfolio spanning the United States, Australia, Canada, China, Europe, Israel, and Japan.
MenoGeniX has no commercial product revenue. The company's capital base consists of approximately $1.1 million in disclosed equity financings across 2012-2016 and a 2018 Phase I SBIR grant from the National Institute on Aging. With 1-10 employees and a single pre-Phase II asset, the stated business model is to advance MNGX-100 through further clinical trials and FDA approval, then commercialize via partnerships, licensing, or acquisition by innovator, biosimilar, or women's healthcare companies — the company is actively soliciting such partners through its website.
MenoGeniX firmographics
Firmographics- Name
- MenoGeniX
- Legal name
- MenoGeniX
- Website
- https://menogenix.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MenoGeniX is a privately-held, clinical-stage biopharmaceutical company developing MNGX-100, a G-CSF analog for treating moderate-to-severe menopausal hot flashes as an alternative to hormone therapy and paroxetine. The company is funded by NIH and equity capital and seeks a commercialization partner.
- Ownership category
- akta.pro rank
MenoGeniX industry classification
Industry- Product category
- Menopausal therapeutics
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Endocrine Hypertension & Neuroendocrine Disorders (HLAKADAN)
Keywords
Where MenoGeniX is headquartered
LocationHeadquarters
- HQ city
- Aurora
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
MenoGeniX business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
MenoGeniX product offering
Product offeringCore offering
MenoGeniX is developing MNGX-100, a biopharmaceutical product containing an analog of the naturally occurring human protein G-CSF (granulocyte colony-stimulating factor). The candidate is intended as an alternative to FDA-approved hormone therapies and antidepressants for treating moderate and severe hot flashes and other vasomotor symptoms in women with naturally occurring or surgically induced menopause. The mechanism is hypothesized to act on the hypothalamus to counteract proinflammatory cytokines elevated in menopausal symptom sufferers.
Product overview
MenoGeniX is a clinical-stage biopharmaceutical company developing a single product candidate, MNGX-100, as an alternative to FDA-approved hormone therapies and antidepressants for treating menopausal hot flashes. MNGX-100 contains a G-CSF analog and is currently in clinical development with a completed Phase I trial and an ongoing Phase Ib/IIa trial funded by the National Institute on Aging (NIA) of the NIH.
Differentiator
Problem solved
Functional benefit
Brands
- MNGX-100: A biopharmaceutical product containing an analog of naturally occurring human protein G-CSF (granulocyte colony-stimulating factor), being developed as a potential treatment for hot flashes and related vasomotor symptoms of menopause.
Products and services
- MNGX-100 MNGX-100 is MenoGeniX's clinical-stage biopharmaceutical product candidate containing an analog of granulocyte colony-stimulating factor (G-CSF), being developed as an alternative to FDA-approved hormone therapy and low-dose paroxetine for women with naturally occurring or surgically induced menopause who experience moderate and severe hot flashes and other vasomotor symptoms. The candidate acts on the hypothalamus to counteract elevated proinflammatory cytokines associated with menopausal symptoms.
Quantifiable outcome
- Phase I trial completed with 30 women with naturally occurring or surgically induced menopause - positive results informing design for larger Phase Ib/IIa trial
Companies that use MenoGeniX
Customer profileSegments2 records
Ideal customer profiles1 record
MenoGeniX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
MenoGeniX partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
MenoGeniX competitors and assessment
Company assessmentDirect peers
- TherapeuticsMD (now Mayne Pharma): Women's health company that developed Bijuva (estradiol/progesterone) and other menopause therapies. Comparable as a women's-health-focused company developing menopause hormone treatments.
- Ogeda (acquired by Astellas): Belgian biotech whose lead asset fezolinetant (now Veozah) was a non-hormonal hot flash treatment acquired by Astellas. Closest historical analogue as a clinical-stage menopause hot-flash biotech that exited via acquisition.
- Astellas Pharma (Veozah/fezolinetant): Commercializes Veozah (fezolinetant), an FDA-approved non-hormonal NK3 receptor antagonist for menopausal vasomotor symptoms. Most direct clinical/competitive analogue for MenoGeniX's MNGX-100 in treating hot flashes.
- Mithra Pharmaceuticals: Women's health biotech with Estetrol-based product Donesta (in development) and marketed Tibelia for menopause symptoms. Direct peer in clinical development of non-hormonal/semi-hormonal menopause therapies.
Broad incumbents
- Pfizer: Markets the hormone therapy Premarin and has historical dominance in menopausal HRT. Broad incumbent providing relevant competitive context for any menopause drug developer.
- AbbVie: Major women's health franchise with hormone therapies (e.g., Lupron) and other reproductive/endocrine products. Broad incumbent against which any menopause therapeutic would compete for prescribing share.
- Myovant Sciences (now Sumitomo Pharma): Developed Oriahnn (elagolix) and other women's health products; acquired by Sumitomo Pharma. Comparable as a women's-health specialty biotech that scaled through large-pharma commercialization.
- Bayer (Women's Health franchise): Sells menopausal hormone therapy products including estradiol patches and Mirena IUS, and has historically invested heavily in women's health R&D. Broad incumbent in the same therapeutic category.
Emerging players
- Endoceutics: Women's health R&D company developing non-hormonal therapies for menopause symptoms (e.g., Duavee, prasterone/Intrarosa). Comparable as a smaller specialist in menopause drug development.
- Sprout Pharmaceuticals: Women's health biotech focused on female sexual dysfunction (Addyi) and other indications. Comparable as a small specialty women's health therapeutic company.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
MenoGeniX social profiles
Digital presenceMenoGeniX financial estimates
Financial estimateRevenue estimate
Valuation estimate
MenoGeniX leadership team
Management profileNumber of profiles
Profiles4 records
MenoGeniX funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MenoGeniX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MenoGeniX
What does MenoGeniX do?
MenoGeniX is developing MNGX-100, a biopharmaceutical product containing an analog of the naturally occurring human protein G-CSF (granulocyte colony-stimulating factor). The candidate is intended as an alternative to FDA-approved hormone therapies and antidepressants for treating moderate and severe hot flashes and other vasomotor symptoms in women with naturally occurring or surgically induced menopause. The mechanism is hypothesized to act on the hypothalamus to counteract proinflammatory cytokines elevated in menopausal symptom sufferers.
Is MenoGeniX a public or private company?
MenoGeniX is a private company. It is classified as venture growth investor backed and is currently operating.
When was MenoGeniX founded?
MenoGeniX was founded in 2010. It employs 1 to 10 people.
Where is MenoGeniX based?
MenoGeniX is headquartered in Aurora, United States, in the North America region.
Who are MenoGeniX's main competitors?
Direct peers on record are TherapeuticsMD (now Mayne Pharma), Ogeda (acquired by Astellas), Astellas Pharma (Veozah/fezolinetant) and Mithra Pharmaceuticals. Broad incumbents are Pfizer, AbbVie, Myovant Sciences (now Sumitomo Pharma) and Bayer (Women's Health franchise). Emerging players are Endoceutics and Sprout Pharmaceuticals.
Does MenoGeniX have an API?
No public API is recorded for MenoGeniX.
What industry is MenoGeniX in?
MenoGeniX's product category is Menopausal therapeutics. Its primary akta.pro industry code is HLAKADAN, Endocrine Hypertension & Neuroendocrine Disorders. Its SIC code is 2836.